ViiV Healthcare teams up with MPP to license patents related to HIV drug cabotegravir
ViiV Healthcare and MPP are actively negotiating on terms of a voluntary licensing agreement, which would help widen…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 May 22
ViiV Healthcare and MPP are actively negotiating on terms of a voluntary licensing agreement, which would help widen…
11 Mar 22
Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…
02 Mar 22
Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…
16 Feb 22
ImmunoGen will receive $13m in upfront payment for initial targets and is eligible to receive an additional $32.5m…
15 Feb 22
The agreement follows the US government’s initial deal for 700,000 doses of Evusheld, which are already being administered…
08 Feb 22
Biogen will obtain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane, along with the marketing authorisation
18 Jan 22
ADC Therapeutics will receive an upfront payment of $30m, and up to $205m in milestone payments, in addition…
07 Jan 22
The collaboration will use Entos’ Fusogenix nucleic acid delivery technology and Lilly's therapeutic cargo to develop nucleic acid…
30 Dec 21
Eplontersen is an investigational ligand-conjugated antisense (LICA) medicine, designed to treat all types of TTR amyloidosis (ATTR)
24 Dec 21
Under the expanded agreement, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of…